Table 2.
Associations of TMEFF2 methylation in serum DNA with the clinicopathological features of NSCLC patients
| Feature | Methylation frequency (%) | p |
|---|---|---|
| All subjects (n = 316) | 29 (9.2) | |
| Age (years) | ||
| ≤ 66 (n = 131) | 10 (7.6) | 0.424 |
| > 66 (n = 185) | 19 (10.3) | |
| Gender | ||
| Male (n = 243) | 20 (8.2) | 0.288 |
| Female (n = 73) | 9 (12.3) | |
| Smoking status | ||
| Ever (n = 249) | 19 (7.7) | 0.066 |
| Never (n = 67) | 10 (14.9) | |
| Histologic types* | ||
| SCC (n = 104) | 8 (7.7) | 0.579 |
| AC (n = 144) | 14 (9.7) | |
| Pathologic stages | ||
| Stage I (n = 67) | 5 (7.5) | 0.584 |
| Stage II–IV (n = 249) | 24 (9.6) |
*
Sixty eight patients including small cell lung cancers, large cell carcinomas, and unidentified non-small cell lung cancers were excluded from the analysis.
SCC, squamous cell carcinoma; AC, adenocarcinoma